Ranbaxy Laboratories expects to achieve sales of Rs 13,000 crore to Rs 13,500 crore for 15 months period ending March 31, 2014. This does not consider any sales accruing form First-to-File (FTFs) which shall be accounted for as they materialize.
The company has reported a net loss of Rs 842.23 crore for the third quarter ended September 30, 2013 as compared to a net profit of Rs 552.19 crore in the same quarter previous year. Total income of the company has decreased by 3.74% at Rs 1470.18 crore for quarter under review as compared to Rs 1527.36 crore for the quarter ended September 30, 2012.
On the consolidated basis, the group has reported a net loss after taxes, minority Interest and share of proflt/(loss) of associates at Rs 454.17 crore as compared to a net profit of Rs 754.17 crore in the same quarter previous year. However, total income of the group rose 1.93% to Rs 2827.73 crore for quarter under review as against Rs 2774.23 crore in corresponding quarter previous year.
The company has reported a net loss of Rs 842.23 crore for the third quarter ended September 30, 2013 as compared to a net profit of Rs 552.19 crore in the same quarter previous year. Total income of the company has decreased by 3.74% at Rs 1470.18 crore for quarter under review as compared to Rs 1527.36 crore for the quarter ended September 30, 2012.
On the consolidated basis, the group has reported a net loss after taxes, minority Interest and share of proflt/(loss) of associates at Rs 454.17 crore as compared to a net profit of Rs 754.17 crore in the same quarter previous year. However, total income of the group rose 1.93% to Rs 2827.73 crore for quarter under review as against Rs 2774.23 crore in corresponding quarter previous year.
No comments:
Post a Comment